

**CURRICULUM VITA**  
**JOHN THOMAS SLEVIN, MD**

(Revised July 1, 2008)

I. **General Information**

Office Addresses:

Department of Neurology	VA Medical Center	FAX: (859) 281-4817
L445 Kentucky Clinic	Neurology Service (127CDD)	E-mail: jslevin@uky.edu
Univ. of Kentucky Med. Ctr.	2250 Leestown Rd	
40536-0284	Lexington, KY 40511	
(859) 218-5028	(859) 381-4920	

Specialty Board: National Board of Medical Examiners; June 1976 #156142  
American Board of Psychiatry & Neurology, Inc. (ABP&N)  
Certified (neurology): June 1984 #26231

Licensure: 30669 Year: 04/02/1979 State: Virginia (Active)  
D23764 Year: 1979 State: Maryland (Inactive)  
21638 Year: 08/18/1981 State: Kentucky (Active)

II. **Education**

09/66 – 05/70	B.A. (Biol), College of Arts & Sciences, Johns Hopkins Univ., Baltimore, MD
09/70 – 08/71	(Ph.D. program, Biochemistry), Dept. Physiological Chem., College of Med., Johns Hopkins University; Baltimore, MD
08/71 – 05/75	MD (Medicine) College of Medicine, West Virginia Univ.; Morgantown, WV
08/97 – 12/99	M.B.A., Gatton College of Business and Economics, University of Kentucky; Lexington, KY

III. **Professional Experiences**

07/75 – 06/76	Intern (Straight Medicine), West Virginia University Hospital; Morgantown, WV
07/76 – 06/79	Resident (Neurology), The University of Virginia Hospital; Charlottesville, VA
07/79 – 06/81	Fellow (Neuropharmacology) Dept. Pharmacology, College of Medicine, The Johns Hopkins University; Baltimore., MD

IV. **Academic Appointments**

07/81 – 06/86	Assistant Professor of Neurology Department of Neurology, University of Kentucky Medical Center
07/81 – Pres	Research Associate Sanders-Brown Center on Aging, University of Kentucky Medical Center

04/82 – 06/86	Assistant Professor of Pharmacology Department of Pharmacology, University of Kentucky Medical Center
09/83 – Pres	Faculty (Neurotoxicology) Graduate Center for Toxicology, University of Kentucky
07/86 – 06/93	Associate Professor of Neurology, Department of Neurology (Primary) Associate Professor of Pharmacology, Department of Pharmacology (Secondary), University of Kentucky Medical Center
07/86 – Pres	Member, Graduate Faculty [Assoc. 1983-86], University of Kentucky
07/93 – Pres	Professor of Neurology, Department of Neurology (Primary) Professor of Pharmacology, Department of Molecular & Biomedical Pharmacology (Secondary), University of Kentucky Medical Center
07/03 – Pres	Research Associate, Morris K. Udall Parkinson's Disease Research Center of Excellence, University of Kentucky, Lexington, KY
04/07 – Pres	Director of Clinical Research, Morris K. Udall Parkinson's Disease Research Center of Excellence, University of Kentucky, Lexington, KY

#### V. Hospital or Clinical Appointments

07/81 – Pres	Staff Neurologist, Department of Neurology, University of Kentucky Hospital
07/81 – Pres	Staff Neurologist (7/8), Dept. of Neurology, Veterans Administration Medical Center, Cooper Drive Division; Lexington, KY
09/96 – 08/97	Consulting Staff Privileges, Cardinal Hill Rehabilitation Hospital, Lexington

#### VI. Consulting Activity

07/79 – 06/81	Neurological Consultant, Woodrow Wilson Rehabilitation Center Fishersville, VA
07/79 – 06/81	Medical Consultant Montebello State Center, Baltimore, MD
07/82 – Pres	Associate Medical Staff, Division of Maternal & Child Health, Commonwealth of Kentucky; Frankfort, KY
07/85 – 06/94	Medical Review Board, Transportation Cabinet, Commonwealth of Kentucky; Frankfort, KY
03/00	Advisory Panel, Managing Psychotic Symptoms in Parkinson's Disease; Creative Educational Concepts, Inc.; Lexington, KY
07/97 – Pres	Consulting Neurologist; Federal Medical Center, Bureau of Prisons; Lexington

#### VII. Teaching Activity

02/83 – Pres	Lecturer Continuing Medical Education Program, University of Kentucky
<i>Courses</i>	
07/81 – 06/93	Lecturer/Participant, NEU 821 (Neurol Basic Science) NEU 831 (Basic Clinical Neurology)
07/81 – Pres	Administrator (Med. Stud. Electives) NEU 815 [1st Yr], 825 [2nd Yr], 835 [3rd Yr], 850 – 899 [4th Yr]
07/81 – Pres	Neurology Grand Rounds (Director: 7/1/90 - 6/30/93)
08/82 – Pres	Lecturer, Department of Pharmacol. PHA 825 (Med. Stud. Pharmacol. Course)
01/87 – Pres	Lecturer, Department of Pharmacol. PHA 658 (Advanced Neuropharmacology)
07/88 – Pres	Course Director, Department of Neurology, NEU 852 (Research in Neurology)
08/89 – 12/93	Course Director, NEU/ANA/PHA/BIO 605 (Contemporary Neurosci.)
01/92 – Pres	Lecturer, Graduate Center for Toxicol., PHR/TOX 780 (Neurotoxicol Seminar)
01/92 – Pres	Lecturer, Department of Anatomy, ANA 516 (Anatomy of the Nervous System)
01/94	Course Director, Department of Anatomy, ANA 636 (Systems Neuroscience)
08/95 – 06/04	Course Director, Department of Neurology MD 832/833 (Clinical Neurosci)

01/96 – Pres	Course Director, NEU/ANA/PHA 606 (Mechanisms of Neurologic Disease)
02/98 – Pres	Lecturer, Department of Pharmacology, PHA 630 (Special Topics Pharmacol)
10/13/98	Lecturer, Geriatric Pharmacy, PHR813/GRN513 (2 hour elective)
05/21/05	Lecturer, Psychopharmacology & Mental Health Diagnosis, RC 558 (Summer Intercession)
09/05 – Pres	Lecturer, Parkinson's disease & other movement disorders, PAS 654
02/06 – Pres	Lecturer, (1) Parkinson's disease and (2) Epilepsy, PHR 966
11/06 – Pres	Lecturer, Parkinson's disease, ANA/GRN/PGY/PHA 710 (Aging of the nervous system)
09/07	Lecturer, Medical and Psychosocial Aspects of Rehabilitation, RC 515

### *Supervision of Post-doctoral Fellows*

07/82 – 06/85	David L. Sparks, Ph.D. [Currently: Sun Health Research Institute, Sun City, AZ]
09/84 – 07/86	Changiz Geula, Ph.D. [Currently: Professor of Neuroscience, Northwestern University]
06/86 – 09/87	Sabiha Khatoon, Ph.D. [Currently: Research Associate, Institute for Basic Research in Developmental Disabilities, Staten Island, NY]
07/86 – 12/87	Mauro Zurini, Ph.D. [Currently Staff Scientist, Novartis Pharma AG, Basle, Switzerland]
07/90 – 06/91	Ashok J. Chavan, Ph.D. [Currently Owner, small business Bio-tech Firm]
06/03 – 05/04	Allison W. Weaver, MD [Currently Private Practice of Neurology, Owensboro, KY]
07/07 – 12/07	Chad M. Domangue, MD [Currently Interventional Pain Management Fellowship]

### *Medical Student Summer Research*

06/85 – 08/85	John C. Rand; <i>Quantitative histologic and neurochemical measures of noradrenergic systems in Alzheimer's disease</i> , NIH: Students in Hlth. Professions Training Grant
06/85 – 08/85	Gwendolyn White; <i>Effect of prenatal Pb exposure on hippocampal noradrenergic synaptic markers in hippocampus</i> , March of Dimes Medical Student Summer Fellowship
06/86 – 08/86	Earl Robbins; <i>New model of gestational Pb toxicity</i> , March of Dimes Medical Student Summer Fellowship
06/86 – 08/86	Patrick A. Jarvie; <i>Effect of 6-OHDA lesions of substantia nigra on K<sup>+</sup>-induced DA release in rat nucleus basalis magnocellularis</i> , NIH: Students in Health Professions
06/92 – 08/92	Sandra A. Umhauer; <i>Effect of okadaic acid on hippocampal L-glutamate release in kindled &amp; control animals</i> , Bertha LeBus Educat. & Charitable Trust Fund

### *Undergraduate Student Research*

01/86 – 05/86	Robert E. Forrester; <i>Binding of quinolinic acid derivatives to rat hippocampus</i> , Oswald Scholarship
06/87 – 12/87	Thomas C. Logan; <i>Long-term enhancement of K<sup>+</sup>-evoked release of L-glutamate in entorhinal kindled rats</i> , VAMC Work-study Program + Sr. Independent Research

01/88 – 12/88	Christopher Meredith; <i>Effect of phorbol esters on hippocampal L-glutamate release</i> , VAMC Work-study Program + Sr. Independent Study (biology)
06/92 – 08/92	Gricelly Vargus; <i>Effect of intraventricular nitroprusside on rate of entorhinal kindling</i> , Grad. Ctr. for Toxicol. Undergrad. Summer Res. Experience
06/92 – 08/92	Maricelly Vargus; <i>Effect of okadaic acid on Ca<sup>++</sup> independent hippocampal L-glutamate release</i> , Grad. Ctr. for Toxicol. Undergrad. Summer Res. Experience
06/93 – 08/93	Karen G. Calfee; <i>A possible role for protein phosphatase 2A in epileptogenesis</i> , Grad. Ctr. for Toxicol. Undergrad. Summer Res. Experience

### *High School Student Research*

08/96-05/97	Jonathon Clark; <i>Protein Kinase C isozyme compartmentation in chronically kindled rats.</i>
-------------	---

## VIII Advising Activity

### *Faculty Advisor - Medical Students*

08/85 – 05/89	Patrick A. Jarvie
08/86 – 05/90	Earl Robbins, Jill M. Wade
08/87 – 05/91	David Miller
08/88 – 05/92	Joseph Hartig, Sandra Hensley, Paul Hester
08/85 – 05/92	Gregory N. Barnes (M.D./Ph.D. Program)
08/90 – 05/94	Donna Dean
08/91 – 05/95	Sandra A. Umhauer
08/92 – 05/96	Matthew Nicholls
08/97 – 05/01	Michael Schlossberg

### *Other - Medical Students*

1998- Pres	Advisor, Student Interest Group in Neurology (SIGN), UKMC Chapter
------------	---

### *Faculty Advisor - Graduate Students [Ph.D.]*

08/85 – 05/92	Gregory N. Barnes Thesis: <i>The role of calcium ion-dependent kinases and protein phosphatase 2A in the kindling model of epilepsy</i> ; [M.D./Ph.D. Program, Biochemistry, Co-advisor with T.C. Vanaman, Ph.D.]
08/90 – 02/95	James C. Pendergrass Thesis: <i>The effects of the chronic ingestion of low levels of inorganic mercury(II) complexed with EDTA on the rodent neuronal cytoskeleton: Possible role of these forms of environmental mercury exposure in the etiology of Alzheimer's disease</i> ; Ph.D. Program, Graduate Center for Toxicology]

### *Ph.D. Advisory Committee*

1989	Tina M. Forrester, Ph.D.; Grad. Ctr for Toxicology
1989	Jana C. Henson, Ph.D.; Grad. Center for Toxicology
1992	Cynthia A. Crawford, Ph.D.; Exp. Psych.[outside memb.]
1993	Trupti Deshmukh, Ph.D.; Pharmaceut.Sci, Col of Pharm.
1993	Debra J. Gunnensen; Biochemistry, Col. of Med.
1995	Mary L. Mazzanti; Pharmacology, College of Medicine
1996	Kelley Kiningham; Grad. Ctr. for Toxicology
1996	Xuezheng Xie, Ph.D.; Grad Center for Toxicology
1997	Cecilia Kearns; Anatomy & Neurobiology [outside member]
1997	Eric M. Blalock; Pharmacology, College of Medicine

2000	Mary R. Holtz; Grad Center for Toxicology
2001	Melina V. Jones; Immunology & Microbiology
2007	Lyn R. Tindall; Rehabilitation Sciences

## IX Administrative Activity and University Service

### *Lexington VAMC*

1981 – 1984	Medical Records Committee, (Acting Chair, 1983)
1981 – 1984	Infection Control Committee
1981 – 1990	Radiation Safety Committee
1981 – 1984	Animal Care Subcommittee, Research Service; Chair: 10/01/82 - 09/30/84
1983 – 1986	Research & Development Committee, Research Service
1984 – 1986	Chair, Travel Subcommittee, Research Service
1986 – 1988	Budget Subcommittee, Research Service
1989 – 1990	Equipment Subcommittee, Research Service
1990 – 1993	Research & Development Committee, Chair: 10/01/91– 09/30/92
1990 – 1991	Chair, Space Subcommittee, Research Service
1992 – 1993	Chair, Travel Subcommittee, Research Service
1993 – 1995	Equipment Subcommittee, Research Service
1993 – 1995	Professional Standards Board
1994 – Pres	Pharmacy and Therapeutics Committee
1995 – Pres	Space Subcommittee, Research Service
1996 – 1999	Research & Development Committee, Chair: 10/01/98 – 09/30/99
2002 – 2005	Research & Development Committee, Chair: 10/01/03 – 09/30/04

### *University of Kentucky*

1986	College of Medicine Search Committee, Assoc. Dean for Res. & Basic Sciences, UKMC
1987 – 1988	College of Med. Self-study, CME Subcommittee, UKMC
1987 – 1996	College of Med. Pharm. & Therap. Committee, UKMC
1988 – 1990	Search Committee for Chairman, Dept. of Pharmacol., UKMC; Chair: 1989/90
1989 – 1993	College of Med., Medical Scientist Training Program Committee, UKMC
1989 – 1992	Committee to Establish a Graduate Program in Neurosciences, UKMC
1990 – 1992	Alzheimer's Disease Research Center (ADRC), Executive Committee, Sanders-Brown Center
1990 – 1992	ADRC Advisory Committee, Sanders-Brown Center
1990 – 1993	Elected Member, Faculty Council, UK College of Medicine
1991 – 1992	Departmental Review and Search Committee for Chairman, Dept. of Anatomy & Neurobiology, UKMC
1991 – 1993	Task Force: Mechanisms of Disease & Treatment; Medical School Curriculum Revision Program, UKMC
1992	Faculty Issues Associated with Research Development Committee for Dept Chairs' Retreat on Research, UKMC
1993 – 1994	Secretary/Treasurer, Department of Neurology KMSF <i>Committee of the Whole.</i> ; member <i>ex officio</i> , Budget Subcommittee
1993 – 1998	College of Medicine Graduate Studies Committee, UKMC
1993	Neurosciences Institute Steering Committee, UKMC
1993 – 2000	Epilepsy Program Review Committee, UKMC
1994 – 1996	Department of Neurology Grand Rounds Steering Committee, UKMC
1994 – 1997	Department of Neurology Practice Plan Executive Committee, UKMC
1995 – 1996	Tenure & Promotions Committee, UK College of Medicine
1996 – 2004	UKHMO Managed Care Committee, UKHE

1997 – 1998	Quality Integration Council - Physical Restraints Work Team
1997 – 2000	Tenure & Promotions Committee, UK College of Medicine
1997	Search Committee, Graduate Center for Toxicology Director
1997	Curriculum subcommittee for review of Neuroscience (MD 817)
1998	Department of Biochemistry 6-Year Review Committee
1998 – 2001	Elected Member, Faculty Council, UK College of Medicine; Secretary/Treasurer 2000-2001
1998– 2000	Academic Council, UK Medical Center
2000 – Pres	CPX (MSIII Clinical Performance Examination) Committee
2001 – 2003	Faculty Self-study Committee, LCME Reaccreditation
2001 – 2002	Search Committee for Chair, Dept. of Physiology, UKMC
2002 – 2004	Medical Center Clinical Sciences Area Academic Advisory Committee
2003	Search Committee for Chair, Dept. of Internal Medicine, UKMC
2003 – 2004	Search Committee for Director of Women's Health Center and the Gloria W. Singletary Endowed Chair in Women's Health Research, UKMC
2004 – Pres	Finance Committee, Department of Neurology
2004 – Pres	Non-indemnified Clinical Trials Risk Committee; Chair
2004 – Pres	Kentucky Neuroscience Orthopaedic Institute, Co-Director, Center for Movement Disorders
2004 – 2005	Clinical Research Task Force – Operational Norms for Clinical Research, Co-Chair
2005 – 2006	Department of Internal Medicine 6-Year Review Committee
2006 – 2009	Tenure & Promotions Committee, UK College of Medicine
2008	Spinal Cord & Brain Injury Research Center 6-year Review Committee, Chair

## X Special Assignments

1986	Site Visit, Prog. Project; VAMC Sepulveda, CA; 3/5-6
1986 – 2000	Coordinator of Research Planning, Department of Neurology, UKMC
1988	College of Medicine Research Retreat, Cumberland Falls State Park; 11/7-8
1992	Development of computer software for problem based learning set, Medical School Curriculum Revision Program: → <i>Parkinson's Disease/Movement Disorders</i> → <i>Epilepsy/Anticonvulsants</i>
1997	Safety and Monitoring Committee: <i>Intravenous IGF-1 infusion in head injury</i> ; 12/1/93-11/30/98; 1st yr: \$138,682, entire period: \$620,410.
2005	Interviewer: Assistant Dean for Clinical Research/Director Clinical Research Organization
2006	Sanders-Brown ADRC Pilot Grant Review Committee

## XI Awards and Honors

1970 – 1971	PHS Predoctoral Traineeship in Biochemistry
1971 – 1972	Southern Medical Association Medical Student Scholar
1977 – 1978	NIH Postdoctoral Traineeship in Neurology, #NS 05120
1979 – 1981	NINCDS Individual Postdoc. Fellowship, #5 F32 NS 06328
1982 – 1987	NINCDS Teacher-Investigator Develop. Award #NS 00732
1983	Walter O. Klingman Lecturer in Neurology, University of Virginia
1985	Sigma Xi Research Honorary
1985 – 1988	AMA Physician's Recognition Award, On-going Certification
1990 – 1993	
1988	Third Place, University of Kentucky Student Research Award to Patrick A. Jarvie for research work in Dr. Slevin's laboratory
1988	University of Kentucky Faculty Award

1989	Fellow, American Academy of Neurology
1990	Elected Active Member, American Neurological Association
1991	First Place, UK Neuroscience Day Poster Presentation Award to James C. Pendergrass for research work in Dr. Slevin's laboratory
1997	Master Teacher Award, designation in three areas: Leadership, Innovation, Teaching
1999	Clinical Clerkship Teaching Award
2000	Elected Member, Beta Gamma Sigma academic honor society of AACSB - The International Association for Management Education
2005	Jeanne and Robert Nyere Epilepsy Research Professorship
2007	Best Doctors in America® 2007-2008

## XII Professional Activity and Public Service

1977 – Pres	American Academy of Neurology [AAN] Geriatric Section: 1989 - pres; Clerkship Consortium: 1996 - 2003
1980 – Pres	American Assoc. for the Advancement of Science [AAAS]
1981 – Pres	Society for Neuroscience; President, Bluegrass Chapter, 1990-1993
1985 – 2000	Sigma Xi Research Honorary; Treasurer, Univ. of Kentucky Chap. 1986-1989
1985 – Pres	International Society for Neurochemistry [ISN]
1986 – Pres	American Society for Pharmacology and Experimental Therapeutics [ASPET]
1986 – 1990	American Society for Neurologic Investigation [ASNI]
1987 – Pres	International Brain Research Organization [IBRO]
1988 – 1994	Examiner, American Board of Psychiatry and Neurology, Inc.
1990 – Pres	American Neurological Association [ANA]
1985 – Pres	Medical Advisor, Parkinson's Disease Support Group of Lexington
1993	Essential Tremor Study Group [PI: W.C. Koller, M.D.]
2002 – Pres	VA Parkinson's Disease Consortium
2002 – Pres	Advisor to the Board, Parkinson's Support Center of Kentuckiana
2003 – Pres	American Epilepsy Society
2005 – Pres	Parkinson's Study Group

### *Review Boards*

1983 – 1986	College of Medicine Research Committee, UKMC; 7/1/83 - 6/30/86
1988	Research Advisory Group A, VAMC, Washington, D.C.; 7/1 - 12/31
1989 – 1991	Tobacco & Health Research Inst. Technical Advisory Committee, University of Kentucky
1994 – 1997	Research Advisory Group A, VAMC, Washington, D.C.; 10/01/94 - 09/30/97
2007 – Pres	VA Neurobiology C Merit Review Subcommittee Study Section

### *Ad hoc Reviewer*

#### **Granting Foundations:**

Commonwealth of Virginia Ctr. on Aging, Alzheimer's Related Diseases Research Award Fund  
 March of Dimes  
 Merit Review Board in Neurobiology, VAMC  
 National Science Foundation  
 NIAAA, Biochemistry, Physiology, and Medicine Subcommittee  
 UKMC Markey Cancer Center  
 UKMC Sanders Brown Center on Aging

## Merit Review Appeals Board, VAMC

**Scientific Journals:**

Annals of Neurology Science	Life Science Neuroscience	Brain Research Neurochemical Research
Neurochemistry International	Neuroscience Research Com.	Neurology
J Neuropath & Exp Neurology	Epilepsia	Epilepsy Research
Clinical Neuropharmacology	J Molecular Neuroscience	Neurobiology of Aging
NeuroMolecular Medicine	Trends in Pharmacological Sciences	

**Guest Editor:**

Journal of Pharmacy Practice – August 2007 issue

**XIII Speaking Engagements***Local*

- 1982 02/17: Dementias associated with aging; Social Work Service Inservice Program; VAMC, Leestown Div.
- 1983 07/29: Neurologic Emergencies; Annual Internal Medicine Acute Care Conference, UKMC  
10/11: Neurotransmitter changes in kindled seizures; Department of Anatomy Seminar Series, UKMC
- 1984 07/20: Neurologic Emergencies; Annual Internal Medicine Acute Care Conference, UKMC  
10/15: Update on research & treatment of Parkinson's disease; Lexington Parkinson's Dis. Support Grp
- 1985 02/25: Parkinson's disease update; Gerontology Grand Rounds, Dept. of Medicine, UKMC  
04/15: Update on research & treatment of Parkinson's disease; Lexington Parkinson's Dis. Support Grp  
08/09: Neurologic Emergencies; Annual Internal Medicine Acute Care Conference, UKMC  
09/24: Initiation of therapy for Parkinson's disease; Department of Family Practice, UKMC
- 1986 02/27: Biogenic amine abnormalities in Alzheimer's disease; Dept. of Pharmacol. Seminar Series, UKMC  
03/15: Pharmacology of pupillary function; Dept. of Ophthalmology Seminar Series, UKMC  
07/23: Mechanisms of epileptogenesis; Society for Neuroscience, Bluegrass Chapter  
10/30: Synaptic mechanisms of epileptogenesis; Dept. of Physiology & Biophysics Seminar Series, UKMC
- 1987 01/20: Parkinson's disease; Donovan Scholars Prog., Donovan Forum, Sanders-Brown Ctr on Aging, UK  
02/22: Current concepts: Gilles de la Tourette Syndrome; Tourette Syndrome Association  
05/20: Movement disorders; Department of Psychiatry Seminar Series, UKMC  
11/04: Recent advances in Parkinson's disease; WBKY Radio
- 1988 02/29: Epilepsy: Fact and fiction; WBKY Radio
- 1989 03/29: Biochemical aberrations in Alzheimer's disease; Alpha Omega Alpha Medical Honorary  
06/30: Role for Prot. Kinase C in epilepsy & epileptogenesis; Dept. of Pharmacol. Seminar Series, UKMC  
06/14: Second messenger systems in neural tissue; Division of Nephrol. Summer Seminar Series, UKMC
- 1990 03/01: Parkinson's disease; Off Our Rockers (TV show), CH 9  
03/08: Parkinson's disease: New Drugs; CH 27 News  
04/02: Perturbations of Protein Kinase C and a unique phosphatase in models of epileptogenesis; Grad. Center for Toxicology Seminar Series  
08/09: Neurological Manifestations of Drugs and Toxins; Emergency Medicine Seminar Series  
10/23: Alzheimer's disease,  $\beta$ -tubulin, and mercury; Sanders-Brown Center on Aging Seminar Series  
11/20: Alzheimer's disease,  $\beta$ -tubulin, and mercury; Dept. Anatomy and Neurobiology Seminar Series
- 1991 07/8-9: Huntington's Disease; CH 27 News  
10/14: Update on research & treatment of Parkinson's disease; Lexington Parkinson's Dis. Support Grp  
11/26: Parkinson's Disease; Department of Family Practice; Noon Conference Series
- 1992 11/14: Update on research & treatment of Parkinson's disease; Lexington Parkinson's Dis. Support Grp
- 1993 01/29: Common movement disorders; Dept. of Physical Medicine & Rehabilitation  
02/04: Common movement disorders: Division of Neurosurgery Grand Rounds  
09/27: Approach to headache in the Emergency Department; Department of Emergency Medicine  
10/11: New medications in treatment of Parkinson's disease; Lexington Parkinson's Dis. Support Grp

- 1994 02/08: The role of dopamine agonists in the management of Parkinson's disease; seminar for Lexington neurologists in private practice  
06/23: Huntington's disease and other hyperkinetic movement disorders; Div.of Neurosurg. Grand Rounds  
08/02: Movement disorders in children; Pediatric Specialty Conferences  
08/16: Seizure disorders in children; Pediatric Specialty Conferences  
11/30: The central nervous system: A primer; Opportunity Workshop of Lexington; Lexington
- 1995 04/17: The medical management of Parkinson's disease; Internal Medicine Noon Conference  
09/21: Approach to headache in the Emergency Department; Department of Emergency Medicine  
10/09: Surgical & medical treatment of Parkinson's disease; Lexington Parkinson's Disease Support Grp
- 1996 04/16: Understanding Parkinson's Disease; Sanders Brown Center on Aging Healthy Lifestyle Seminars  
09/09: Surgical & medical treatment of Parkinson's disease; Lexington Parkinson's Disease Support Grp.  
12/03: Approach to headache in the Emergency Department; Department of Emergency Medicine
- 1997 06/09: Parkinson's disease: New questions, new answers; Lexington Parkinson's Disease Support Grp  
07/15: Surgical & medical treatment of Parkinson's disease; Primary Care In-service; Lexington VAMC
- 1998 05/21: Evaluation and medical management of tremor; Neurosurgery Grand Rounds; UKMC  
09/14: Newer treatments for the management of PD; Lexington Parkinson's Disease Support Grp
- 1999 03/11: Regulation of the neurosecretory process by phosphorylation; Pharmacology Seminar; UKMC  
09/13: PD: Questions and Answers; Lexington Parkinson's Disease Support Grp  
11/09: Advances in PD: Neuroscience and Clinical Medicine Meet; Clinical Neuroscience Club; UKMC
- 2000 06/08: Parkinson's disease; Off Our Rockers (TV show), aired on Cable 3 17 times 7/9 - 7/29.
- 2002 03/13: Medical management of Parkinson's disease; Internal Medicine Noon Conference; UKMC  
11/06: Parkinson's disease and parkinsonism; Psychiatry Didactics; UKMC  
11/07: Medical & surgical management of Parkinson's disease; Neurosurgery Grand Rounds; UKMC  
11/11: PD: Questions and answers; Lexington Parkinson's Disease Support Group
- 2003 03/04: The effect of neurological illness on the vocational rehabilitation process; OWL, Inc.  
09/08: PD: Questions and answers; Lexington Parkinson's Disease Support Group
- 2004 04/13: Parkinson's disease and the role of GDNF in its treatment; Donovan Scholars Speaker Program  
08/06: Newer treatment modalities for Parkinson's disease; Internal Medicine Grand Rounds, UKMC  
10/29: Surgical alternatives to the treatment of Parkinson's disease; UK CME  
10/29: Horizon's in the treatment of Parkinson's disease; UK CME
- 2005 04/05: Medical management of Parkinson's disease; Internal Medicine Noon Conference; UKMC  
09/12: Recent advances in PD & the GDNF experience; Lexington Parkinson's Disease Support Group  
10/19: Parkinsonism and dementia; Noon Seminar; Sanders Brown Center on Aging  
11/14: Parkinson's disease & drug product development: End-of-dose failure for Amgen's Liatermin®; MBA Program; Gatton College of Business and Economics, University of Kentucky
- 2006 03/02: Parkinson's disease: End-of-dose failure for Amgen's Liatermin®?; Dean's Clinical Research Seminar; UKMC  
09/11: Research opportunities/new medications for PD; Lexington Parkinson's Disease Support Group  
09/13: Medical management of Parkinson's disease; Internal Medicine Noon Conference; UKMC  
10/07: Contribution opportunities for Parkinson's disease research; Pilots Club of Lexington  
12/04: Collaborations: Working together and taking the lead; Women in Science and Medicine Luncheon Series; UKMC
- 2007 03/29: Parkinson's disease & drug product development: A story of Amgen's Liatermin®; UK COM Neuroscience Club.  
03/30: Parkinson's disease: Approaching the bicentennial; Internal Medicine Grand Rounds; UKMC  
05/12: Parkinson's disease: 200 years and still looking (Public Lecture); WT Young Library, UKMC  
06/09: Dystonia (Public Lecture); WT Young Library, UKMC  
11/29: Ethics & drug product development; Gatton College of Business, UKMC

### *State*

- 1982 06/04: Diagnosis and treatment of dementia; Annual Meeting, KY Osteopathic Med Assoc; Lexington  
1983 11/16: Managing Seizures; Family Practice Lectures, Continuing Medical Education Series; Lexington  
1985 01/28: Drug-induced movement disorders & Parkinson's disease; King's Daughter's Hospital; Frankfort

- 1986 01/22-23: (1) Movement disorders and (2) Seizure disorders; Family Practice Lectures, UKMC CME Series; Lexington  
05/19: Seizure disorders; Knox County Hospital; Barbourville
- 1987 11/09: Recent advances in Parkinson's disease; King's Daughter's Hospital; Frankfort
- 1988 02/28: Update on Parkinson's disease; Berea Hosp.; Berea  
09/22: Update on Parkinson's disease; Marymount Hospital; London  
10/06: Update on Parkinson's disease; Trover Clinic; Madisonville
- 1989 09/11: Diagnosis and treatment of movement disorders; King's Daughter's Hospital; Frankfort  
10/02: Diagnosis & treatment of movement disorders; James B. Haggin Mem. Hospital CME; Shakertown
- 1990 02/15: Parkinson's Disease; Scott County General Hospital UKMC CME; Georgetown  
09/01: Parkinson's Syndrome in symposium: Rehabilitation Management for the Primary Care Physician; UKMC CME; Lexington  
09/18: Diagnosing movement disorders; Marymount Hospital [UKMC CME]; London  
12/04: Diagnosis and treatment of Parkinson's Disease; Hardin Memorial Hospital CME; Elizabethtown
- 1991 04/16: Diagnosis and treatment of Parkinson's Disease; Harrison Memorial Hospital CME; Cynthiana  
08/18: Current concepts on the treatment of Parkinson's Disease; Kentucky Academy of Family Physicians Summer Seminar; Lexington  
10/05: Parkinson's Disease: Frontiers in diagnosis; Kentucky Academy of Physician Assistants; 15<sup>th</sup> Annual Continuing Medical Education Symposium; Lexington
- 1992 06/25: Diagnosis and treatment of Parkinson's Disease; Bourbon County Medical Society; Berea  
08/26: Current treatment of Parkinson's Disease; Eastern KY Physicians Prestonsburg
- 1993 03/28: Parkinson's Disease; Updates in Geriatrics, College of Medicine CME; Lexington
- 1995 10/14: Headache; Neurology for the Primary Care Provider; College of Medicine CME; Lexington
- 1996 03/17: Evaluation of Tremor; Topics in Geriatric Medicine; College of Medicine CME; Lexington  
09/10: Diagnosis and Treatment of Parkinson's Disease; AHEC CME; St Claire Medical Ctr; Morehead
- 1997 03/22: Parkinson's Disease; Issues in Geriatric Neurology for the Primary Care Provider; Lexington  
11/22: Surgical & medical treatment of Parkinson's disease; Neurology for the Primary Care Provider; UKMC/CME; Lexington
- 1999 08/22: Parkinson's Disease; *27 HealthFirst Magazine*; WKYT-TV  
10/14: Progress in Parkinson's disease; Pikeville Methodist Hospital Neurological Symposium; Pikeville, KY
- 2000 10/27: Advances in the Medical Management of Parkinson's Disease; 2000 Annual Neurology Conference; UKMC/CME; Lexington, KY
- 2003 12/03: 15<sup>th</sup> Annual Skills Training, Dept. of Mental Health/Mental Retardation Pre-admission Screening and Resident Review Staff; University of Kentucky Council on Aging; Lexington, KY
- 2004 10/01: Future therapies: Role of GDNF in Parkinson's disease; University of Louisville School of Medicine; Louisville, KY  
11/12: Pathophysiology, current treatment and future therapies for Parkinson's disease; Movement Disorders Symposium/Medtronic; Lexington, KY
- 2005 09/19: Parkinson's disease update: Pathophysiology & treatment; Pattie A. Clay Hosp.; Richmond, KY
- 2006 05/06: Diagnosis & medical management of Essential Tremor; International Essential Tremor Fdn; Lexington, KY  
11/04: Parkinson's disease; Health Matters Radio Show; Morehead State Public Radio; Morehead, KY
- 2007 11/09: Keynote address: Epilepsy research; 2007 Epilepsy Brainstorm Summit; Louisville, KY
- 2008 06/18: Parkinson's disease & Parkinson Plus Syndromes; University of Cincinnati Movement Disorder Program; Cincinnati, OH

### *National*

- 1983 02/25: Evaluation of syncope; 14th Annual Family Medicine Review; Lexington, KY  
04/08: Excitatory amino acid neurotransmitters and neurotoxins: Role in epilepsy; 3rd Annual Neurosciences Symposium; Lexington, KY  
11/18: The pharmacology of epilepsy: Role of neurotransmitter alterations in etiology and treatment; The Walter O. Klingman Lectureship in Neurology, University of Virginia; Charlottesville, VA

- 1984 03/09: The pharmacology of epilepsy: Role of neurotransmitter alterations in etiology and treatment; Neuroscience Seminar Series, Dept. of Neurology, West Virginia University; Morgantown, WV  
11/15: A user's guide to current anti-convulsant medications; 15th Annual Family Medicine Review; Lexington, KY
- 1985 02/08: The excitatory amino acid and kindling models of partial epilepsy; Dept. of Neurology, University of Wisconsin; Madison, WI  
08/02: Pathology, diagnosis & treatment of Parkinson's disease; Smith Cty Medical Society; Carthage, TN  
09/11: Initiation of therapy in Parkinson's disease; Merk, Sharp & Dohme, Inc.; Tallahassee, FL  
10/09: Current concepts in Parkinson's disease; Robinson Memorial Hospital; Kent, OH
- 1986 03/07: Excitatory amino acids, divalent cations and kindling; VAMC Sepulveda; Sepulveda, CA
- 1987 02/25, 05/20, 10/28: Evaluating MS and other "Neuropathies"; 18th Annual Family Medicine Review; Lexington, KY  
4/4-5: Common clinical neurological issues; Amer. College of Physicians Annual Mtg; New Orleans, LA
- 1988 02/21, 05/22, 10/30: Evaluation and treatment of Parkinson's disease; 19th Annual Family Medicine Review; Lexington, KY  
02/25, 05/26, 11/3: Neurological implications of AIDS; 19th Ann. Family Medicine Review; Lexington, KY
- 1989 06/12: Current concepts in Parkinson's disease; Dept. of Internal Medicine, Univ. of Kansas; Wichita, KA  
Movement disorders of basal ganglia origin; HCA Wesley Medical Center; Wichita, KA
- 1990 11/02: Intracellular mechanisms of epileptogenesis; Dept. of Neurol, West Virginia University; Morgantown, WV
- 1993 10/09: Doctor, my headache won't stop; National Stroke Association; Lexington, KY
- 1995 07/16: Epilepsy and Parkinson's Disease; Internal Medicine Board Review; UK CME; Lexington, KY
- 1997 02/25, 05/20, 11/11: Parkinson's Disease Update; 28th Annual Family Medicine Review; Lexington, KY
- 1998 08/14: New medications for the treatment of Parkinson's disease; Dept. of Neurol, West Virginia University; Morgantown, WV
- 2000 02/22, 05/25: Parkinson's & Movement Disorders Update; 31<sup>st</sup> Annual Family Medicine Review; Lexington, KY
- 2001 10/02: Managing Psychotic Symptoms in Parkinson's Disease; Creative Educational Concepts, Inc.; Oklahoma City, OK.  
10/11: Managing Psychotic Symptoms in Parkinson's Disease; Creative Educational Concepts, Inc.; Minneapolis, MN.  
10/18: Managing Psychotic Symptoms in Parkinson's Disease; Creative Educational Concepts, Inc.; Richmond, VA.
- 2005 06/29: A clinical picture of Parkinson's disease: Disease progression & current research; 22<sup>nd</sup> Annual Summer Series on Aging; Sanders-Brown Center on Aging, UK; Lexington  
09/11: "Cure Interrupted?" Interviewed by correspondent Leslie Stahl for **60 Minutes** broadcast segment
- 2006 04/13: Parkinson's disease: need for new therapy; Lexington Conference on RNA Therapy for Neurodegenerative Diseases; Lexington, KY

### *International*

- 1981 05/28: Role of excitatory amino acid neurotransmitters in Tourette's syndrome; 1st International Gilles de la Tourette Syndrome Symposium; New York, NY
- 1985 09/04: Excitatory amino acids, divalent cations and the kindling model of epilepsy; Symposium: Excitatory Amino Acids and Epilepsy; Fillerval, France
- 2004 06/05: A proteomic approach to the molecular analysis of kindling; Sixth International Conference on Kindling; Victoria, BC.
- 2005 04/28: Site specific delivery of trophic factors in the brain: Kentucky studies; Lexington Conference on Translational Neuroscience; Lexington, KY
- 2007 04/18: Parkinson's disease: 200 years and still looking; 2007 Lexington Conference/Translational Neuroscience/Trophic factor therapy for Parkinson's disease; Lexington, KY
- 2008 04/03: Parkinson's disease and PD+ syndromes; IV Seminario Internacional de Neurociencias; Quito, Ecuador.

## XIV Research and Creative Productivity

### *Publications*

#### **Abstracts:**

01. SLEVIN, J.T., Faught, R.E., Hanna, G.R., and Lee, S.I. *EEG abnormalities in migraine: An epiphenomenon of headache or medication?* Abstract, 1979 Annual Meeting, American EEG Society
02. Coyle, J.T., SLEVIN, J.T., London, E.D., and Collins, J. *Characterization of neuronal recognition sites for [<sup>3</sup>H]-kainic acid.* Conference of Psychopharmacology and Biochemistry of Neurotransmitter Receptors. Tucson, AZ, 1980
03. SLEVIN, J.T., Johnston, M., Biziere, K., and Coyle, J.T. *Specific binding of [<sup>3</sup>H]-glutamate and [<sup>3</sup>H]-kainate in the granulo-prival mouse cerebellum.* Soc.Neurosci.Abstr. 6:8, 1980
04. Coyle, J.T., Zaczek, R., SLEVIN, J.T., and Collins, J. *Neuronal receptor sites for kainic acid: Correlations with neurotoxicity.* International Symposium on GABA and Glutamate as Transmitters. Cagliari, Italy, 1980.
05. SLEVIN, J.T. and Coyle, J.T. *Glutamate receptors and striatal function.* 1st International Gilles de la Tourette Syndrome Symposium. New York, 1981
06. SLEVIN, J.T. and Coyle, J.T. *Characterization of excitatory amino acid receptors in cerebellum.* Neurology 31(2):119, 1981
07. SLEVIN, J.T. and Ferrara, L. *Specific binding of [<sup>3</sup>H]-L-glutamic acid in the hippocampus of kindled rats.* Soc.Neurosci.Abstr. 8:1013, 1982
08. SLEVIN, J.T. *Excitation of hippocampal neurons by valproic acid not associated with [<sup>3</sup>H]-L-glutamic acid binding.* Neurology 4(2):216, 1983
09. Sparks, D.L., SLEVIN, J.T., and Kasarskis, E.J. *Neurotransmitter changes in hypothalamus: Potential mediators of anorexia in zinc deficiency.* J.Neurochem. 41:S60, 1983
10. Sparks, D.L., SLEVIN, J.T., and Kasarskis, E.J. *Hypothalamic neurotransmitters during anorexia induced by acute dietary zinc restriction of adult rats.* Soc.Neurosci.Abstr. 9:192, 1983
11. Sparks, D.L. and SLEVIN, J.T. *Dopaminergic synaptic alterations in nucleus basalis associated with Alzheimer's disease.* Neurology 34(S1):281, 1984
12. Sparks, D.L., SLEVIN, J.T. and Kasarskis, E.J. *Neurochemical alterations in hypothalamus associated with anorexia of zinc deficiency.* Neurology 34(S1):198, 1984
13. Sparks, D.L. and SLEVIN, J.T. *Aromatic monoamines in nucleus basalis of Meynert: Changes related to Alzheimer's disease and to normal aging.* Soc.Neurosci.Abstr. 10:271, 1984
14. SLEVIN, J.T., Sparks, D.L. and Fain, J. *Amantadine prevents dopamine receptor supersensitivity in rats.* Soc.Neurosci.Abstr. 10:559, 1984
15. Roszman, T., Sparks, D.L., SLEVIN, J.T., Markesbery, W.R., Jackson, J.C. and Cross, R.J. *The presence of serotonin receptors on murine lymphocytes and macrophages.* Soc.Neurosci.Abstr. 10:726, 1984
16. Kasarskis, E.J. and SLEVIN, J.T. *Effect of zinc status on markers of excitatory amino acid neurotransmission in hippocampus.* Soc.Neurosci.Abstr. 10:228, 1984
17. Sparks, D.L., SLEVIN, J.T. and Walker, R.F. *Noradrenergic modulation of pineal serotonin (5HT) synthesis and secretion in vitro.* The Physiologist 27(4):227, 1984
18. Sparks, D.L., SLEVIN, J.T. and Hunsaker, III, J.C. *3-Methoxytyramine (3-MT) in the putamen as a gauge of the post-mortem interval (PMI).* Amer.Acad.of Forensic Sci. 37(GO88):89, 1985
19. SLEVIN, J.T. and DeKosky, S.T. *Stability of sialogangliosides in kindled hippocampus.* Neurology 5(S1):157 1985
20. Sparks, D.L. and SLEVIN, J.T. *Unilateral lesion of human substantia nigra: A biochemical-histological correlation.* Neurology 35(S1):222, 1985
21. Sparks, D.L., SLEVIN, J.T., Hunsaker, III, J.C. and Oeltgen, P.R. *Comparison of techniques for determining postmortem interval.* Clin.Chem. 31:957, 1985
22. 23. Sparks, D.L. and SLEVIN, J.T. *Tyrosine hydroxylase activity in post-mortem samples of human putamen and caudate nucleus.* Soc.Neurosci.Abstr. 11:1203, 1985
23. Geula, C. and SLEVIN, J.T. *Differential alterations in dopaminergic markers in the nucleus basalis and striatum of rats with 6-OHDA lesions of the substantia nigra.* Soc.Neurosci.Abstr. 11:902, 1985

24. Kasarskis, E.J., Forrester, T.M. and SLEVIN, J.T. *Hippocampal zinc during amygdalar kindling in the rat.* Epilepsia 26:513, 1985
25. Sparks, D.L., SLEVIN, J.T., Oeltgen, P.R. and Hunsaker, III, J.C. *Comparison of chemical methods for determining PMI: Putaminal 3-methoxytyramine (3-MT) changes vs. vitreous humour  $K^+$  accumulation.* Amer.Acad.of Forensic Sci. 38:xx, 1986
26. Geula, C. and SLEVIN, J.T. *Excitatory amino acid markers altered in the frontal cortex of Alzheimer's patients.* Neurology 36(S1):266, 1986
27. Sparks, D.L. and SLEVIN, J.T. *Age and SDAT-related alterations of dopamine and serotonin synaptic markers in the nucleus basalis of Meynert.* Neurology 36(S1):223, 1986
28. Forrester, T.M., SLEVIN, J.T. and Kasarskis, E.J. *Persistent elevations in hippocampal zinc following amygdalar kindling in rats.* Neurology 36(S1):129, 1986
29. Kadaba, P.K. and SLEVIN, J.T. *Mechanism of action of triazoline anticonvulsants.* Pharmaceutical Res. 3(S):24, 1986
30. SLEVIN, J.T., Geula, C. and DeKosky, S.T. *Substantia nigra 6-OHDA lesions affect choline acetyltransferase (ChAT) levels in rat nucleus basalis magnocellularis.* Soc.Neurosci.Abstr. 12:234, 1986
31. Geula, C. and SLEVIN, J.T. *Effect of entorhinal kindling on  $K^+$  or kainic acid stimulated release of amino acids in rat hippocampus.* Soc.Neurosci.Abstr. 12:344, 1986
32. Nonneman, A., Butterfield, D.A., Elder, T., SLEVIN, J.T. and Forester, R.E. *Excitotoxin lesions of rat hippocampus: Quinolinic acid and related compounds.* Soc.Neurosci.Abstr. 12:89, 1986
33. SLEVIN, J.T., Khatoon, S. and Haley, B.E. *Decreased availability of the exchangeable GTP binding site of the  $\beta$ -subunit of brain tubulin in Alzheimer's disease.* Neurology 37:330, 1987
34. Campbell, S.R., Khatoon, S., Haley, B.E. and SLEVIN, J.T. *Inability of brain microtubules in Alzheimer's disease to cold-depolymerize.* Soc.Neurosci.Abstr. 12(2):1326, 1987
35. Khatoon, S., SLEVIN, J.T. and Haley, B.E. *GTP binding to the beta-subunit of tubulin is greatly reduced in Alzheimer's disease.* Fed.Proc. 46:2137, 1987
36. Jarvie, P.A., Wade, J.M. and SLEVIN, J.T.  *$Ca^{+2}$ -dependent release of amino acids in hippocampal subfields quantified by HPLC.* Soc.Neurosci.Abstr. 13(2):1288, 1987
37. Khatoon, S., SLEVIN, J.T., Haley, B.E. and Iqbal, K. *Interaction of nucleotide photoaffinity analogues with Alzheimer brain protein.* First International Symposium on Familial Alzheimer's Disease Research, Research Foundation Symposium Abstract, 1988
38. SLEVIN, J.T. and Kasarskis, E.J. *Coadministration of intracerebro-ventricular zinc blocks n-methyl-D-aspartate-induced electrographic and behavioral seizures.* Neurology 38(S1):106, 1988
39. SLEVIN, J.T., Barnes, G.N. and Vanaman, T.C. *Perturbation of hippocampal membrane-associated activity of protein kinase C and an inhibitor after a generalized seizure.* Soc.Neurosci.Abstr. 14(1):574, 1988
40. Zurini, M., Kasarskis, E.J., SLEVIN, J.T. and Vanaman, T.C. *A novel high-affinity zinc binding peptide from rat brain.* Trans.Am.Soc. Neurochem. 19:153, 1988
41. SLEVIN, J.T., Vanaman, T.C. and Barnes, G.N. *Dysregulation of membrane systems for phosphorylation-dephosphorylation in the kindling model of epilepsy.* Soc.Neurosci.Abstr. 15(1):455, 1989.
42. Barnes, G.N., Vanaman, T.C. and SLEVIN, J.T. *Synaptic plasma membrane phosphoprotein phosphatase 2A<sub>0</sub> may regulate autophosphorylation of cAMP and  $Ca^{+2}$ /CAM dependent kinases.* Soc.Neurosci.Abstr. 15(1):194, 1989
43. Kadaba, P.K. and SLEVIN, J.T. *ADD17014, a new triazoline anticonvulsant effective against complex partial seizures.* Pharmaceutical Res. 6(S):42, 1989
44. Barnes, G.N., SLEVIN, J.T. and Vanaman, T.C. *Increased  $Ca^{+2}$ /calmodulin kinase II autophosphorylation in the kindling model of epilepsy.* Neurology 40(S1):329, 1990
45. Gunnensen, D.J., SLEVIN, J.T. and Haley, B.E. *Novel proteins in Alzheimer's diseased brain may be due to pathological modification of  $\beta$ -tubulin.* Fed.Proc. 4(7):A2151, 1990
46. Duhr, E., SLEVIN, J.T. and Haley, B.E. *Low level HgEDTA complex specifically blocks [ $^{32}$ P]8N<sub>3</sub>GTP interaction with human brain tubulin.* Fed.Proc. 4(7):A2151, 1990
47. Savage, D.D., Tso-Olivas, D.Y. and SLEVIN, J.T. *Long-lasting decrease in hippocampal mossy fiber zinc after entorhinal kindling in rat.* Soc.Neurosci.Abstr. 16(2):1107, 1990
48. Barnes, G.N., Vanaman, T.C. and SLEVIN, J.T. *Amino acid analysis and sequencing of rat brain protein phosphatase 2A.* Soc.Neurosci.Abstr. 16(2):1181, 1990

49. Kadaba, P.K. and SLEVIN, J.T. *ADD17014, a unique triazoline anticonvulsant, effective in the kindling model of epilepsy and an inhibitor of EAA neurotransmission*. Annual Meeting American Chemical Society, 20th. August, 1990.
50. SLEVIN, J.T., Gunnensen, D.J., Duhr, E. and Haley, B.E. *Implication for mercury in the alteration of  $\beta$ -tubulin observed in Alzheimer's disease*. Ann. Neurol. 28:230, 1990.
51. Shih, W.J., SLEVIN, J.T., Schleenbaker, R.E., Magoun, S., Mills, B.J., and Ryo, U.Y. *Surface and volume three-dimensional displays of Tc-99m HM-PAO brain SPECT images in stroke patients by gamma camera*. Society of Nuclear Medicine 38th Annual Meeting, 1991.
52. Duhr, E., Pendergrass, C., Kasarskis, E., SLEVIN, J.T. and Haley, B. *Hg<sup>2+</sup> induces GTP-tubulin interactions in rat brain similar to those observed in Alzheimer's disease*. Fed.Proc. 5(4):A456, 1991.
53. Gunnensen, D.J., SLEVIN, J.T. and Haley, B.E. *Preliminary characterization of a novel Alzheimer's disease associated protein*. Fed.Proc. 5(4):A456, 1991.
54. Tita, T.T., Kadaba, P.K., SLEVIN, J.T. and Deshmukh, T.R. *Tissue distribution studies of ADD17014, a novel triazoline anticonvulsant*. American Association of Pharmaceutical Scientists, 1991 Meeting.
55. Gunnensen, D.J., Haley, B.E. and SLEVIN, J.T. *Preliminary characterization of a novel Alzheimer's disease associated protein*. Soc.Neurosci.Abstr. 17(1):690, 1991.
56. SLEVIN, J.T., Barnes, G.R., Farrar, Y.J., Alcalá, R.M. and Vanaman, T.C. *Generalized tonic-clonic seizures induced in rats by intraventricular administration of okadaic acid*. Soc.Neurosci.Abstr. 18(1):555, 1992.
57. Farrar, Y.J.K., SLEVIN, J.T., Vanaman, T.C. *Affinity purification of brain pp2A using the thiophosphorylated peptide substrate*. Fed.Proc. 7(7):A1157, 1993.
58. Pendergrass, J.C., Duhr, E.F., SLEVIN, J.T. and Haley, B.E. *Meso-2,3-Dimercaptosuccinic acid (DMSA) partially restores [<sup>32</sup>P]8N<sub>3</sub>GTP- $\beta$ -tubulin interactions to both Alzheimer's diseased (AD) brains and to HgEDTA treated control brains*. Fed.Proc. 7(4):A626, 1993
59. Pendergrass, J.C., Duhr, E.F., Haley, B.E. and SLEVIN, J.T. *Effect of chronic ingestion of micromolar HgCl<sub>2</sub> & HgEDTA complex on rodent neuronal cytoskeleton*. Soc.Neurosci.Abstr. 19(1):193, 1993
60. Bruce, A.J., Blanc, E.M., Boling, W.W., SLEVIN, J.T. and Mattson, M.P. *Disruption of gap junctions adversely affects neuronal and glial susceptibility to excitotoxic and metabolic insults*. Epilepsia 37(Supp.5):53, 1996.
61. SLEVIN, J.T., Whiteheart, S.W. and Vanaman, T.C. *Response of hippocampal synaptic vesicle docking and fusion proteins to [Ca]<sub>e</sub> & depolarization in kindled and naive rats*. Soc.Neurosci.Abstr. 22(3):1992, 1996.
62. Baker, R.S., Sun, W.S., Hasan, S.A., Abell, K.M., SLEVIN, J.T., Chuke, J.C. and Porter, J.D. *Eyelid kinematics in Parkinson disease*. Investigative Ophthalmology and Visual Science 38:568, 1997.
63. Cibula, J.E., Kasarskis, E.J., Trevathan, E., and SLEVIN, J.T. *Electroencephalogram recorded during death*. American Clinical Neurophysiology Society Meeting, October 1998.
64. SLEVIN, J.T., Matveeva, E.A., Whiteheart, S.W., and Vanaman, T.C. *Serine/threonine phosphorylation of NSF is associated with calcium<sup>+2</sup>-dependent K<sup>+</sup>-stimulated release of L-glutamate in neocortical synaptosomes*. Ann. Neurol. 46:487, 1999.
65. Blalock, E.M., Chen, K-C., Landfield, P.W., and SLEVIN, J.T. *Kindling chronically depresses L-type Ca<sup>2+</sup> channel activity and L-type  $\alpha_{1D}$  gene expression: Single channel correlations in hippocampal CA1 neurons*. Soc.Neurosci.Abstr. 25(1):1111, 1999.
66. Matveeva, E.A., SLEVIN, J.T., Vanaman, T.C, and Whiteheart, S.W. *Uncoupling ATPase activity of NSF from SNAP/SNARE complex disassembly*. Molec. Biol. Cell 11:107a, 2000.
67. Daugherty K.K., Ryan M., SLEVIN, J.T. *Topiramate Use in Essential Tremors*. Presented at American Society of Health-Systems Pharmacists Midyear Clinical Meeting. December 2001.
68. SLEVIN, J.T., Matveeva, E.A., and Whiteheart, S.W. *Accumulation of 7S SNARE complexes in hippocampal synaptosomes from chronically kindled rats*. AAN 54<sup>th</sup> Annual Mtg. April 18, 2002
69. Foley, C.D., SLEVIN, J.T. and Kasarskis, E.J. *Divalproex-induced parkinsonism: A retrospective review of cases*. The Movement Disorder Society's 7th International Congress of Parkinson's Disease and Movement Disorders. November 10-14, 2002.
70. SLEVIN, J.T., Whiteheart, S.W. and Vanaman, T.C. *Detection of altered proteins in kindled epilepsy using a combined genomic/proteomic approach*. AAN 55<sup>th</sup> Annual Mtg. April 1, 2003.

71. SLEVIN, J.T., Whiteheart, S.W. and Vanaman, T.C. *Detection of altered proteins in kindled epilepsy using a combined genomic/proteomic approach*. Proteomic Solutions in Cellular and Developmental Biology and Medicine: Stowers Institute for Medical Research. May 2-4, 2003
72. SLEVIN, J.T., Young, A.B., Gerhardt, G.A. and Gash, D.M. *Unilateral intraputamenal administration of recombinant-methionyl human glial cell-line derived neurotrophic factor to treat idiopathic Parkinson's disease*. ANA 128<sup>th</sup> Annual Meeting, On-site Program, p. 41. October 19-23, 2003.
73. Sauer, M., Harrison, M.J., Stratton, T.D., and SLEVIN, J.T. *The effect of student choice on faculty evaluation ratings in a third year neurology clerkship*. The Generalists Meeting, November 8-9, 2003.
74. Walton, A.A., Loveland, A.D., Umberger, G., Smith, C.D., SLEVIN, J.T., Gash, D.M. and Grondin, R. *Long-term Motor Memory Retention in Rhesus Macaques Mirrors That of Humans on a Similar Hand-retrieval Task*. Program #771.5 2004 Abstract Viewer/itinerary planner. Washington, DC: Society for Neuroscience, 2004.online.
75. Gash, D.M., Zhang, Z., Grondin, R., SLEVIN, J.T., Smith, C.D., Kryscio, R., Young, A.B., and Gerhardt, G.A. *Bilateral effects from continuous unilateral intraputamenal infusion of GDNF in advanced Parkinson's disease patients replicates results in non-human primate animal models of parkinsonism*. Program #1011.3 2004 Abstract Viewer/itinerary planner. Washington, DC: Society for Neuroscience, 2004.online.
76. Walton, A.A., Branham, A.S., SLEVIN, J.T., Gash, D.M. and Grondin, R. *Use of an automated video-tracking software system to detect age-related differences in motor function of the Rhesus macaque*. Program #757.13 2005 Abstract Viewer/itinerary planner. Washington, DC: Society for Neuroscience, 2005.online.
77. Bailey, J., Ryan, M., Steinke, D., Kasarskis, E. and SLEVIN, J. *Valproic acid use and parkinsonian symptoms in a Veterans Affairs population*. Presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting, 12/2005.
78. Mattingly, M., SLEVIN, J.T., Bird, A., Blonder, L., Gash, D., Gerhardt, G., Kryscio, R., Young, B. and Schmitt, F. *Motor skill improvement in Parkinson's disease with GDNF infusion*. International Neuropsychological Society, Zurich, July 2006.
79. Matveeva, E.A., Vanaman, T.C., Whiteheart, S.W. and SLEVIN, J.T. *The Accumulation of 7S SNARE Complexes (7SC) and increases of SV2 in hippocampal synaptosomes from kindled rats is blocked in levetiracetam-treated animals*. Ann. Neurol. 62(suppl 11):S31, 2007.
80. Hudson, M., Gash, D.M., Rutland, K., Sullivan, P.G., Bing, G., Cass, W., Pandya, J.D., Liu, M., Choi, D-Y., Hunter, R.L., Gerhardt, G.A., Smith, C.D., SLEVIN, J.T., and Prince, T.S. *Trichloroethylene: a possible neurotoxin and risk factor for parkinson's disease*. Program #482.14 2007 Abstract Viewer/itinerary planner. SanDiego, CA: Society for Neuroscience, 2007.online.
81. Blonder, L.X., SLEVIN, J.T., Smith, C.D., Schmitt, F.A., Kryscio, R.J., Lineberry, M.J., Martin, C., Andersen, A.H. *Amygdala activation to emotional faces in unmedicated Parkinson patients: Preliminary findings*. International Neuropsychological Society. Honolulu, HI, 2007.
82. Blonder, L.X., SLEVIN, J.T., Smith, C.D., Schmitt, F.A., Kryscio, R.J., Lineberry, M.J., Martin, C., Andersen, A.H. *Increased amygdala response during emotional processing in unmedicated PD patients*. 12<sup>th</sup> International Congress of Parkinson's Disease and Movement Disorders. Chicago, IL, 2008.

### Full Length Manuscripts:

01. Lepore, F.E., Sanborn, G.E. and SLEVIN, J.T. *Pupillary dysfunction in myasthenia gravis*. Annals of Neurology 6:29-33, 1979
02. Lepore, F.E., McKiernan, J.E. and SLEVIN, J.T. *Bilateral nystagmus in syringobulbia*. Annals of Ophthalmology 12:304-306, 1980
03. SLEVIN, J.T., Faught, R.E., Hanna, G.R. and Lee, S.I. *EEG abnormalities in Migraine*. Headache 21:251-254, 1981
04. SLEVIN, J.T. and Coyle, J.T. *Ontogeny of receptor binding sites for [<sup>3</sup>H]-glutamic acid and [<sup>3</sup>H]-kainic acid in rat cerebellum*. J.Neurochem. 37:531-533, 1981
05. SLEVIN, J.T., Johnston, M.V., Biziere, K. and Coyle, J.T. *Methylazoxymethanol acetate ablation of mouse cerebellar granule cells: Effects on synaptic neurochemistry*. Developmental Neuroscience 5:3-12, 1982
06. SLEVIN, J.T., Collins, J., Lindsley, K. and Coyle, J.T. *Specific binding of [<sup>3</sup>H]-L-glutamate to cerebellar membranes: Evidence for recognition site heterogeneity*. Brain Research 249:353-360, 1982
07. Ferkany, J.W., SLEVIN, J.T., Zaczek, R. and Coyle, J.T. *Failure of folate derivatives to displace [<sup>3</sup>H]-kainic acid from its binding sites*. Neurobehavioral Toxicol. and Teratology 4:573-579, 1982

08. SLEVIN, J.T., Collins, J. and Coyle, J.T. *Analogue interactions with the brain receptor labeled with [<sup>3</sup>H]-kainic acid.* Brain Research 265:169-172, 1983
09. Sparks, D.L. and SLEVIN, J.T. *Determination of tyrosine, tryptophan and their metabolic derivatives by liquid chromatography-electrochemical detection: Application of post mortem samples from patients with Parkinson's and Alzheimer's disease.* Life Sciences 36:449-457, 1985
10. SLEVIN, J.T. and Kasarskis, E.J. *Effects of zinc on markers of glutamate and aspartate neurotransmission in rat hippocampus.* Brain Research 334:281-286, 1985
11. Sparks, D.L., Markesbery, W.R. and SLEVIN, J.T. *Age-associated alteration of serotonergic synaptic neurochemistry in rat rostral hypothalamus.* Neurobiology of Aging 6:213-217, 1985
12. SLEVIN, J.T. and Ferrara, L.P. *Lack of an effect of entorhinal kindling on L-[<sup>3</sup>H]-glutamic acid presynaptic uptake and postsynaptic binding in hippocampus.* Experimental Neurology 89:48-58, 1985
13. SLEVIN, J.T. and Ferrara, L.P. *Chronic valproic acid therapy and synaptic markers of amino acid neurotransmission.* Neurology 35:728-731, 1985
14. SLEVIN, J.T. and DeKosky, S.T. *Stability of sialogangliosides in kindled hippocampus.* Experimental Neurology 91:208-211, 1986
15. Walker, R.F., Sparks, D.L., SLEVIN, J.T. and Rush, M.E. *Temporal effects of norepinephrine on pineal serotonin in vitro.* J.Pineal Research 3:33-40, 1986
16. Kasarskis, E.J., SLEVIN, J.T. and Sparks, D.L. *Changes in hypothalamic noradrenergic systems during the anorexia of zinc deficiency.* Biol.Trace Element Res. 9:25-35, 1986
17. Sparks, D.L., Markesbery, W.R. and SLEVIN, J.T. *Alzheimer's disease: decreased aromatic monoamines and spiperone binding in nucleus basalis of Meynert (nbM).* Annals of Neurology 19:602-604, 1986
18. Hunsaker III, J.C., Sparks, D.L. and SLEVIN, J.T. *Putamenal 3-methoxytyramine as a gauge of the post mortem interval.* J.Forensic Pathology 31:962-971, 1986
19. SLEVIN, J.T., Sparks, D.L., Dempsey, R.J., Davis, D.G., Hunsaker III, J.C. and DeKosky, S.T. *Altered striatal dopaminergic metabolism 36 hours after unilateral trauma to the human mesencephalon.* Neurology 37:322-325, 1987
20. Kasarskis, E.J., Forrester, T.M. and SLEVIN, J.T. *Amygdalar kindling is associated with elevated zinc concentration in the cortex and hippocampus of rats.* Epilepsy Research 1:227-233, 1987
21. Geula, C., Jarvie, P.A., Logan, T.C. and SLEVIN, J.T. *Long term enhancement of K<sup>+</sup>-evoked release of L-glutamate in entorhinal kindled rats.* Brain Research 442:368-372, 1988
22. Kadaba, P.K. and SLEVIN, J.T. *Triazolines XV. Anticonvulsant profile of ADD17014, a potentially unique 1,2,3-triazoline antiepileptic drug, in mice and rats.* Epilepsia 29:330-337, 1988
23. Khatoon, S., Campbell, S.R., Haley, B.E. and SLEVIN, J.T. *Aberrant guanosine triphosphate-beta tubulin interaction in Alzheimer's disease.* Ann.Neurology 26:210-215, 1989
24. Geula, C. and SLEVIN, J.T. *Substantia nigra 6-hydroxydopamine lesions alter dopaminergic synaptic markers in the nucleus basalis magnocellularis and striatum of rats.* Synapse 4:248-253, 1989
25. Jarvie, P.A., Logan, T.C., Geula, C. and SLEVIN, J.T. *Entorhinal kindling permanently enhances Ca<sup>2+</sup>-dependent L-glutamate release in regio inferior of rat hippocampus.* Brain Research 508:188-193, 1990
26. Farrar, Y.J.K., Vanaman, T.C. and SLEVIN, J.T. *A phosphatase resistant substrate for the assay of protein kinase C in crude tissue extract.* Biochem. Biophys. Res. Com. 180 (2):694-670, 1991
27. Sparks, D.L., Hunsaker, III, J.C., SLEVIN, J.T., DeKosky, S.T., Kryscio, R. and Markesbery, W.R. *Monoaminergic and cholinergic synaptic markers in the nucleus basalis of Meynert (nbM): Normal age-related changes and the effect of heart disease and Alzheimer's disease.* Ann. Neurology 31:611-620, 1992
28. Shih, W-J, Schleenbaker, R.E., Stipp, V., Magoun, S. and SLEVIN, J.T. *Surface and volume three-dimensional displays of Tc-99m HMPAO brain SPECT images in stroke patients by three-head gamma camera.* Clinical Nuclear Medicine 18:945-949, 1993.
29. Duhr, E., Pendergrass, J.C., SLEVIN, J.T. and Haley, B.E. *HgEDTA complex inhibits GTP interactions with brain  $\beta$  tubulin.* J.Toxicology & Applied Pharmacology 122:273-280, 1993.
30. Ryan, S.J., Smith, C.D. and SLEVIN, J.T. *Magnetic resonance imaging in ochronosis, a rare cause of back pain.* J.Neuroimaging 4:41-42, 1994.
31. *Et alia* author on: Koller, W.C., Busenbark, K., Miner, K. and the Essential Tremor Study Group. *The Relationship of essential tremor to other movement disorders.* Ann Neurology 35:717-723, 1994.
32. Barnes, G.N., SLEVIN, J.T., and Vanaman, T.C. *Rat brain protein phosphatase 2A: An enzyme which may regulate autophosphorylated protein kinases.* J. Neurochem. 64:340-353, 1995.

33. Smith-Swintosky, V.L., Kraemer, P.J., Bruce, A.J., McCants, N., Maki, A., Brown, R.W., Alcala, M., Keller, J., Goodman, Y., SLEVIN, J.T. and Mattson, M.P. *Bacterial alkaloids mitigate seizure-induced hippocampal damage and memory deficits.* Exp. Neurol., 141:287-296, 1996.
34. Smith, C.D., Umberger, G.H., Manning, E., SLEVIN, J.T., Wekstein, D., Marksbery, W.R., Gerhardt, A. and Gash, D.M. *Upper extremity motor performance in human aging quantified by a human motor activities panel.* Neurology, 53:1458-1461, 1999.
35. Ryan, M., SLEVIN, J.T. & Wells, A. *Non-ergot dopamine agonist-induced sleep attacks.* Pharmacotherapy, 20:724-726, 2000.
36. Kluemper, G.T., White, D.K. and SLEVIN, J.T. *Chronic fissural cheilitis: A manifestation of anterior crowding.* Amer J Orthodontics & Dentofacial Orthopedics, 119:71-75, 2001.
37. Ryan, M., Fowler, J.B. and SLEVIN, J.T. *Treatment of psychosis associated with Parkinson's disease.* The Consultant Pharmacist, 16:277-283, 2001.
38. Blalock, E.M., Chen, K-C., Vanaman, T.C., Landfield, P.W. and SLEVIN, J.T. *Epilepsy-induced decrease of L-type Ca<sup>2+</sup> channel activity and coordinate regulation of subunit mRNA in single neurons of rat hippocampal "zipper" slices.* Epilepsy Research, 43:211-226, 2001.
39. Matveeva, E.A., Whiteheart, S.W., Vanaman, T.C. and SLEVIN, J.T. *Phosphorylation of the N-ethylmaleimide Sensitive Factor (NSF) is associated with depolarization-dependent neurotransmitter release from synaptosomes.* J. Biol. Chemistry 276:12174-81, 2001.
40. Haughey, N.J., Nath, A., Mattson, M.P., SLEVIN, J.T. and Geiger, J.D. *HIV-1 TAT through phosphorylation of NMDA receptors potentiates glutamate excitotoxicity.* J. Neurochem. 78:457-467, 2001.
41. Matveeva, E.A., Whiteheart, S.W. and SLEVIN, J.T. *Accumulation of SNARE complexes in hippocampal synaptosomes from chronically kindled rats.* J. Neurochem. 84:621-624, 2003
42. Barnes, G.N. and SLEVIN, J.T. *Glutamate receptor biology: Effect on synaptic connectivity and function in neurologic disease.* Current Medicinal Chemistry, 10:2059-72, 2003.
43. Daugherty, K.K., Ryan, M. and SLEVIN, J.T. *Essential tremor treated with topiramate: A case series.* Hospital Pharmacy, 39:772-5, 2004.
44. SLEVIN, J.T., Gerhardt, G.A., Smith, C.D., Gash, D.M., Kryscio, R., and Young, A.B. *Unilateral Intraputamenal GDNF Improves Bilateral Motor Functions in Patients with Parkinson Disease.* J. Neurosurgery 102:216-222, 2005.
45. Nausieda, P.A., Pfeiffer, R.F., Tagliati, M., Kastenholz, K.V., DeRoche, C. and SLEVIN, J.T. *A multicenter, open-label patient preference study of carbidopa-levodopa orally disintegrating tablets and conventional carbidopa-levodopa tablets.* Clinical Therapeutics 27(1):58-63, 2005.
46. Chebrolu, H., SLEVIN, J.T., Gash, D.M., Gerhardt, G.A., Young, A.B., Given, C.A. and Smith, C.D. *MRI Volumetric and Intensity Analysis of the Cerebellum in Parkinson's Disease Patients Infused with Glial-Derived Neurotrophic Factor (GDNF).* Experimental Neurology 198(2):450-456, 2006.
47. Wilk, J.B. Tobin J.E., Suchowersky, O and the Gene-PD Study Group. *Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: The GenePD Study.* Neurology 67(12):2206-10, 2006.
48. Matveeva, E.A., Vanaman, T.C., Whiteheart, S.W. and SLEVIN, J.T. *Asymmetric Accumulation of Hippocampal 7S SNARE Complexes Occurs Regardless of Kindling Paradigm.* Epilepsy Research 73:266-274, 2007.
49. SLEVIN, J.T., Gash, D.M., Smith, C.D., Gerhardt, G.A., Kryscio, R., Chebrolu, H., Walton, A., Wagner, R.E. and Young, A.B. *Unilateral Intraputamenal GDNF in Patients with Parkinson Disease: Response to One Year of Treatment and One Year of Withdrawal.* J. Neurosurgery, 106:614-620, 2007.
50. Smith, C.D., Walton, A., SLEVIN, J.T., Gerhardt, G.A., Umberger, G., Smoot, K., Schulze, E. and Gash, D.M. *Validation studies of the human movement analysis panel for arm/hand preference.* J. Neurosci. Methods, 165:287-296, 2007.
51. Gash, D.M., Rutland, K., Carter, N. Sullivan, P., Bing, G., Pandya, J., Liu, M., Choi, D-Y., Hunter, R., Gerhardt, G.A., Smith, C.D., SLEVIN, J.T., and Prince, T.S. *Trichloroethylene: Parkinsonism and complex I mitochondrial toxicity.* Annals of Neurology 63:184-192, 2008.
52. Tobin, J.E. and the Gene-PD Study Group. *Haplotypes and gene expression implicate the MAPT region for Parkinson disease: The GenePD Study.* Neurology 71:29-35, 2008.
53. Matveeva, E.A., Vanaman, T.C., Whiteheart, S.W. and SLEVIN, J.T. *Levetiracetam prevents kindling-induced asymmetric accumulation of hippocampal 7S SNARE complexes.* Epilepsia, electronic preprint at <http://www.blackwell-synergy.com/loi/epi>.

54. McNicoll, C.F. and the Gene-PD Study Group. *Huntington CAG repeat size does not modify onset age in familial Parkinson's disease: The GenePD Study*. Movement Disorders, In press.
55. Xu, G. and the Gene-PD Study Group. *R.H. Type-1 Protein Phosphatase Inhibitor 4 (I-4) on Xp11.4-11.3 is Associated with Familial and Idiopathic Parkinson's disease: The GenePD Study*. American Journal of Human Genetics, submitted.
56. Bailey, J., Steinke, D., SLEVIN, J.T., Kasarskis, E.J. and Ryan, M. *Valproic acid use and parkinsonian symptoms in a Veterans Affairs population*. Pharmacotherapy, submitted.
57. DeStafano, A.L. and the Gene PD Study Group. *Replication of Association between ELAVL4 and Parkinson Disease: The Gene PD Study*. Human Genetics, submitted.
58. Mattingly, M.L., SLEVIN, J.T., Blonder, L.X., Gash, D.M., Gerhardt, G.A., Kryscio, R.J., Young, A.B., Bird, A., and Schmitt, F.A. *Motor skill improvement in Parkinson's disease with GDNF infusion*. Neurology, submitted.
59. Blonder, L.X. and SLEVIN, J.T. *Emotional Dysfunction in Parkinson's Disease*. Neuropsychology Review, submitted.

### Book Chapters:

01. Coyle, J.T., Zaczek, R., SLEVIN, J.T. and Collins, J. *Neuronal receptor sites for kainic acid: Correlations with neurotoxicity*. In: Glutamate as a Neurotransmitter (G. DiChiara and G.L. Gessa, eds), Raven Press, New York, pp. 337-346, 1980
02. Coyle, J.T., SLEVIN, J.T., London, E.D., Biziere, K and Collins, J. *Characterization of neuronal recognition sites for [<sup>3</sup>H]-kainic acid*. In: Psychopharmacology and Biochemistry of Neurotransmitter Receptors (R.W. Olson, H.I. Yamamura, E. Usdin, Eds.), Raven Press, New York, pp. 501-513, 1980
03. Biziere, K, SLEVIN, J.T., Zaczek, R., Collins, J.C. and Coyle, J.T. *Kainic acid: Neurotoxicity and receptor interactions*. In: Advances in Pharmacology and Therapeutics II. Vol. I. CNS Pharmacology Neuropeptides (H. Yushida, Y. Hagihara, S. Ebashi, Eds.), Pergamon Press, Elmsford, NY, pp. 271-277, 1982
04. Coyle, J.T., Ferkany, J., Zaczek, R., SLEVIN, J.T. and Retz, K. *Kainic acid: Insight into its receptor-mediated neurotoxic mechanisms*. In: Excitotoxins (K. Fuxe, P. Roberts, R. Schwarcz, Eds.), MacMillan Press, London, pp. 112-121, 1983
05. SLEVIN, J.T., Kasarskis, E.J., Vanaman, T.C. and Zurini, M. *Excitatory amino acids, divalent cations and the kindling model of epilepsy*. In: Excitatory Amino Acids and Epilepsy (R. Schwarcz, Y. Ben-Ari, Eds.), Plenum Press, New York, pp. 587-598, 1986
06. SLEVIN, J.T. *Parkinson's Disease*. In: Saunders Manual of Medical Practice (R.E.Rakel, Ed.), W.B. Saunders, Philadelphia, pp. 1050-1052, 1996.
07. SLEVIN, J.T. *Headache*. In: Adult Neurology: Mosby's Neurology Psychiatry Access Series (J.Corey-Bloom, Ed.), Mosby, St. Louis, MO, 117-139, 1998.
08. Stafstrom, C.E., Prasad, A., Prasad, C., and SLEVIN, J. T. *Progress on understanding the genetics of epilepsy*. In: Genetic Aberrancies and Neurodegenerative Disorders (M. Mattson, Ed.), JAI Press, Inc., Greenwich, CN, 189-241, 1999.
09. SLEVIN, J.T. *Parkinson's Disease*. In: Saunders Manual of Medical Practice Second Edition (R.E.Rakel, Ed.), W.B. Saunders, Philadelphia, pp. 1368-1371, 2000.
10. SLEVIN, J.T., Whiteheart, S.W. and Vanaman, T.C. *A proteomic approach to the molecular analysis of kindling*. In: Kindling 6 (M.E. Corcoran, S.L. Moshe, Eds.) Kluwer Academic/Plenum Publishers, New York, pp. 189-197, 2005.
11. SLEVIN, J.T. and Ryan, M.H. *Chapter 8: Headache*. In: Adult Neurology: Mosby's Neurology Psychiatry Access Series Second Edition (J.Corey-Bloom, Ed.), Mosby, St. Louis, MO, pp. 111-133, 2005.
12. Grondin, R., Zhang, Z., Ai, Y., SLEVIN, J., Young, A.B., Gash, D.M., and Gerhardt, G.A. *Direct delivery of GDNF into the non-human primate and human parkinsonian brain: Success and roadblocks*. In: CNS Regeneration: Basic Science and Clinical Advances, 2<sup>nd</sup> Edition (J.H. Kordower and M.H. Tuszynski, Eds.), Elsevier, Boston, pp. 223-244, 2008.
13. Whiteheart, S.W., Matveeva, E.A., Vanaman, T.C. and SLEVIN, J.T. *Presynaptic Neurotransmission: Alterations in Exocytotic/Secretory Machinery in Kindling*. In: Encyclopedia of Basic Epilepsy Research (P.A. Schwartzkroin, Ed.), Elsevier, Oxford, UK, In press.

14. SLEVIN, J.T. and Ryan, M.H. *Chapter 8: Headache*. In: Clinical Adult Neurology, 3<sup>rd</sup> Edition (J.Corey-Bloom, Ed.), Demos Medical Publishing, New York, In press.
15. Vanaman, T.C., Whiteheart, S.W., Matveeva, E.A., SLEVIN, J.T. *Proteomic approaches to the analysis of protein alterations at the synapse in kindling*. In: Encyclopedia of Basic Epilepsy Research (P.A. Schwartzkroin, Ed.), Elsevier, Oxford, UK, In press.

### **Workbooks, invited peer-reviewed articles, editorials, electronic journals, etc**

01. *Dopamine Agonists in the Management of Parkinson's Disease: Treatment Paradigms and Case Studies*; UK College of Medicine and Rpxperience, Inc. (Tarrytown, NY); Supported by an unrestricted educational grant from GlaxoSmithKline; Release Date: June 1, 2004 Expiration Date: May 31, 2005, 50 pages.
02. SLEVIN, J.T. and Ryan, M.H. *Orally disintegrating Carbidopa-levodopa*. Future Neurology 1(2):137-145, 2006.
03. SLEVIN, J.T., Gash, D.M., Smith, C.D., Gerhardt, G.A., Kryscio, R., Chebrolu, H., Walton, A., Wagner, R. and Young, A.B. *Unilateral Intraputaminal glial cell line-derived neurotrophic factor in Patients with Parkinson Disease: Response to 1 Year each of Treatment and Withdrawal*. Neurosurg Focus 20(5):E1-7, 2006.
04. Ryan, M. and SLEVIN, J.T. *Restless legs syndrome*. American Journal of Health-system Pharmacy 63:1599-612, 2006.
05. Zhao, C., SLEVIN, J.T. and Whiteheart, S.W. Cellular functions of NSF: Not just SNAPs and SNAREs. FEBS Letters 581(11):2140-49, 2007.
06. Ryan, M. and SLEVIN, J.T. *Introduction: Treatment of neurological disorders*. Journal of Pharmacy Practice, 20:115-116, 2007.
07. Ryan, M. and SLEVIN, J.T. *Restless legs syndrome*. Journal of Pharmacy Practice 20(6):430-448, 2007.
08. Latourelle, J.C. and the Gene-PD Study Group. *The G2019S mutation in LRRK2 is not fully penetrant: The GenePD study*. BMC Neurology, Submitted.

### **Letters to the Editor:**

01. SLEVIN, J.T. *Carbon monoxide induced muscle necrosis*. Archives of Neurology 36:523, 1979.
02. Lepore, F.E., Sanborn, G.E. and SLEVIN, J.T. *Asymmetric pupillary slowing and degree of severity in myasthenia gravis - reply*. Annals of Neurology 7:289, 1980.
03. Sparks, D.L., Hunsaker, III, J.C. and SLEVIN, J.T. *Postmortem accumulation of 3-methoxytyramine in the brain*. New Eng.J.Med. 311:540, 1984.
04. SLEVIN, J.T., Gerhardt, G.A., Smith, C.D., Gash, D.M., Kryscio, R. and Young, B. *Research on Parkinson Disease*. J. Neurosurg. 102:401, 2005.
05. Penn, R.D., Dalvi, A., SLEVIN, J.T., Young, B., Gash, D.M., Gerhardt, G.A., Hutchinson, M., and Kelly, P. *GDNF in treatment of Parkinson's disease: response to editorial*. Lancet Neurology 5:202-3, 2006.
06. SLEVIN, J.T., Gehardt, G.A., Smith, C.D., Gash, D.M. and Young, A.B. *GDNF poses troubling questions for doctors, drug maker: response*. Ann Neurol 59(6):989-90, 2006.

### *Grant Activity*

#### **Principal Investigator:**

##### **Basic Research**

- 07/01/81 *The role and regulation of L-glutamic acid as a neurotransmitter in the hippocampus of rats kindled by*  
 06/30/82 *entorhinal electrical stimulation*; Physician's Service Plan (PSP) Research Start-up Grant, UKMC;  
**\$24,064**
- 04/01/82 *Etiologic role of L-glutamate in the kindling model of focal epilepsy*; Research Advisory Group (RAG)  
 03/31/83 Start-up Grant, VAMC; **\$29,600**

- 07/01/82 *The etiologic role of L-glutamate in the kindling model of focal epilepsy*; NINCDS (TIDA) #NS 00732; 06/30/87 **\$212,250** (salary award only)
- 04/01/83 *Glutamatergic synaptic plasticity and kindling: A model of limbic seizures*; VAMC Merit Review; 09/30/85 **\$80,600**
- 07/01/83 *The effect of cigarette smoking on central dopaminergic synapses in the rat*; Tobacco & Health Research 06/30/84 Inst.; **\$35,443**
- 12/01/84 *Cholinergic-aminergic alterations in Alzheimer's disease*, In: Program Project: Biochemical and morpho-04/30/89 logical studies in Alzheimer's disease (Project Director: W.R. Markesbery); NIA #1 PO1 AG 05119; **\$214,524**
- 10/01/85 *Excitatory acidic amino acid neurotransmission and amygdalar kindling*; VAMC Merit Review; **\$71,025** 09/30/87
- 02/01/86 *Effect of 6-OHDA lesions of the substantia nigra on K<sup>+</sup>-induced dopamine release in rat nucleus basalis 06/30/86 magnocellularis*; UKMC Research Fund; **\$5,345**
- 07/01/86 *Neurochemical and pharmacological approaches to kindling*; UKMC-BSRG (NIH); **\$2,489** (equipment 06/30/87 grant)
- 07/01/86 *Neurochemical and pharmacological approaches to kindling*; UKMC Research Fund; **\$17,161** (equipment grant)
- 01/01/87 Unrestricted Research Support; Bertha LeBus Educational and Charitable Trust Fund; **\$5,000** (1/1-02/28/92 6/30/87), **10,000** (7/1/87-6/30/88), **\$5,000** (3/1/89-2/28/90), **\$5,000** (3/1/90-2/28/91), **\$5,000** (3/1/91-2/28/92)
- 10/01/87 *Glutamate: Enhanced Ca-mediated release in epilepsy-receptor photoprobes*; VAMC Merit Review; 09/30/90 **\$141,500**
- 03/17/87 Liquid scintillation system; Commonwealth of Kentucky Bond for Research Equipment; **\$30,000**
- 05/01/89 *Nucleotide-tubulin interactions in Alzheimer's brain*, In: Program Project: Biochemical, morphological, 04/30/94 and trace element studies in Alzheimer's disease (Project Director: W.R. Markesbery); NIA #2PO1AG 05119-05; **\$329,492**
- 10/01/90 *Epilepsy: kindling-induced aberrant second messenger signaling cascades*; VAMC Merit Review; 09/30/93 **\$153,527**
- 07/01/91 *Role of brain specific proteins in nerve function*; NINDS; [Co-P.I., T.C. Vanaman, P.I.]; NS21868-06; 6/30/95 **\$558,333**
- 10/01/93 *Epilepsy: kindling-induced aberrant second messenger signaling cascades*; VAMC Merit Review; 09/30/96 **\$225,300**
- 07/01/97 *Epilepsy: long-term effect of kindling on the neurosecretory apparatus*; Medical Center Research Fund; 06/31/98 **\$15,000**.
- 07/01/98 *Epilepsy: long-term effect of kindling on the neurosecretory apparatus*; Chancellor's Office Interim 03/31/99 Funding; **\$27,400**.
- 10/01/99 *Long-term effect of kindled epilepsy on the neurosecretory apparatus*; VAMC Merit Review; 1<sup>st</sup> year 09/31/02 direct: **\$111,700**; Total period: **\$287,700**; Funded, 4<sup>th</sup>%.
- 03/01/02 *Altered expression of secretory machinery encoding mRNAs in fully kindled rats*; Microarray Facility Pilot Program Proposal; 1<sup>st</sup> year direct **\$5,087**
- 01/01/04 *Long-term effect of kindled epilepsy on the neurosecretory apparatus*; VAMC Merit Review; 1<sup>st</sup> year 12/31/06 direct: **\$169,000**; Total period: **\$510,500**.
- 07/01/06 *Effect of Levetiracetam on SNARE Complex Assembly during Epileptogenesis*; UCB Pharma; 1<sup>st</sup> year 06/30/07 direct: **\$35,709**; Total period: **\$35,709**.

10/01/07 *Long-term effect of kindled epilepsy on the neurosecretory apparatus*; VAMC Merit Review; 1<sup>st</sup> year 09/31/11 direct: **\$164,900**; Total period: **\$539,900**.

### **Clinical Research**

10/02/86-*Master agreement order for the clinical evaluation of antiepileptic drugs*; Epilepsy Branch, NINDS 09/30/91 #N01-NS-7-2335; T.C. Foster, Co-P.I.

03/01/90 *Effect of intravenous infusion of calcium, phenytoin, and verapamil on plexopathy-induced tremors*; General Clinical Research Center; **\$480**

07/01/92 *A double-blind, placebo controlled, parallel group study of oral doses of ropinirole for six-months in the treatment of early Parkinsonian patients not treated with L-Dopa, protocol #101468/054*; SmithKline Beecham Pharmaceuticals; **\$49,660** [10 patients]

09/01/93 *A double-blind, placebo controlled, 6 month extension study of 101468/054 to evaluate the long-term efficacy and safety of ropinirole in early Parkinsonian patients not receiving dopaminergic therapy. Protocol # 101468/055*; SmithKline Beecham Pharmaceuticals; **\$26,567** [10 patients]

09/30/95 *Study of Neurontin: Titration to Effect, Profile of Safety*; Warner-Lambert Pharmaceuticals; **\$2,100**. 08/31/97

01/15/99 *A phase III multicenter, double blind, parallel-group placebo controlled study of the effect of riluzole 50 mg bid or 100 mg bid for two years on the progression of parkinson's disease in 1050 patients*; Rhône-Poulenc Rorer Inc; 1<sup>st</sup> year direct **\$38,125**; Total period **\$161,538**.

09/01/99 *A phase III multicenter, double blind, parallel-group placebo controlled study of the effects of riluzole 50 mg bid or 100 mg bid for two years on the progression of Parkinson's disease in patients treated with L-DOPA or dopamine agonists*; Rhône-Poulenc Rorer Inc; 1<sup>st</sup> year direct **\$38,476**; Total period **\$153,904**.

09/01/00 *A Phase II, randomized, double-blind, active-controlled, dose-escalation study to determine the maximum well-tolerated dose of ropinirole controlled-release (CR) in Parkinson's Disease patients not receiving other dopaminergic therapies*; Parexel International/SkyePharma; Total period **\$22,650 (\$4,530/patient)**.

02/07/02 *Within-subject, dose-escalation trial of continuously infused intraputamenal (IPu) recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) for the treatment of subjects with idiopathic Parkinson's disease*; Department of Anatomy and Neurobiology

08/09/02 *Within-subject, dose-escalation trial of continuously infused intraputamenal (IPu) recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) for the treatment of subjects with idiopathic Parkinson's disease*; Amgen, Inc.; Total period **\$376,620 (\$37,662/patient)**

01/22/03 *Amendment 2 (Extended Trial) Within-subject, dose-escalation trial of continuously infused intraputamenal (IPu) recombinant-methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) for the treatment of subjects with idiopathic Parkinson's disease*; Amgen, Inc.; Total period **\$281,020 (\$28,102/patient)**

04/01/03 *Use of Tests of Timed Motor Function to Evaluate Level of Effect of NeuroAIDS*; Institute of AIDS 03/31/04 Research; **\$9,000**

02/01/04 *A multicenter, open-label trial to assess subject preference of PARCOPA Carbidopa/Levodopa Orally Disintegrating Tablets compared to conventional Carbidopa/Levodopa Tablets in subjects with stable Parkinson's disease*; SchwarzPharma, Inc.; **\$25,716 (\$3,214/patient)**.

00/00/00 *Genetic linkage study in Parkinson's disease*; NIH (NS36711-06); R.H Meyers, P.I.; **\$1250**/recruited sib 06/30/07 pair; PI for this clinical site.

10/04/05 *A multi-center, observational safety registry of subjects with idiopathic Parkinson's disease previously treated with intraputamenal infusion of Liatermin*; Amgen, Inc.; **\$76,104 (\$7,610.40/patient)**.

01/01/06 *Study antidepressants in Parkinson's disease (SAD-PD)*; NIH/NINDS 5RO1NS046487 [Parkinson's 12/30/09 Disease Study Group]; I.H. Richard, P.I.; **\$90,059.90 (\$6004/patient)**; P.I. for this clinical sight.

11/01/06 *A multi-center, randomized, double-blind, placebo-controlled parallel group study of the efficacy, safety 10/30/08 and tolerability of E2007 in levodopa treated Parkinson's disease patients*; Eisai, Inc.; **(\$14,533/patient)**.

09/01/07 *A multi-center, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of 08/30/09 E2007 as an adjunctive therapy in levodopa treated Parkinson's disease patients with motor fluctuations*; Eisai, Inc.; **(\$14,533/patient)**.

### **Educational Research**

07/01/84 *Aromatic monoamines in Alzheimer nucleus basalis*; UKMC PSP Post-doctoral Fellowship; **\$14,000** (to 06/30/85 support D. Larry Sparks, Ph.D.)

07/01/90 *Investigation of beta tubulin abnormalities in Alzheimer's disease*; UKMC PSP Post-doctoral Fellowship; 06/30/91 **\$15,000** (to support Ashok J. Chavan, Ph.D.)

07/01/01 *Digitizing radiographic brain images for computer-based testing*; Instructional Technology Grant 06/30/02 Program, UKMC; **\$5,000**.

### **Co-Investigator:**

#### **Basic Research**

07/01/79 *Microchemical pathology of developing hippocampus*; NINCDS #5 RO1NS 16009; N.H. Bass, P.I.; 12/30/82 **\$263,036** (Co-I in last yr)

10/01/83 *Analysis of toxic and essential trace metals - ALS (Kasarskis) & The effect of cigarette smoking on 09/30/84 central dopaminergic synapses in rat (Slevin)*; Central Research Resources - Basic Research Services Grant; Univ. of Kentucky Graduate School; **\$3,000**

12/01/83 *Changes in hypothalamic noradrenergic systems during the anorexia of Zinc deficiency*; Univ. of 11/30/84 Kentucky Grad. Sch. Res. Funds; E.J. Kasarskis, P.I.; **\$5,000**

09/01/85 *Tissue specimen core*, In: Program Project: Alzheimer Disease Research Center; NIA #1 P50 AG 05144; 08/05/90 W.R. Markesbery, P.I.; **\$46,708**

07/01/86 *Quantification of excitatory amino acid binding in the Alzheimer brain using video image analysis*; 06/30/87 Sanders-Brown Research Center; B.F. Siskin, P.I.; **\$5,000**

04/01/87 *Metabolism & pharmacology of triazolone anticonvulsants*; NINCDS #R01 NS 124750; P.K. Kadaba, 03/31/90 P.I.; **\$170,493**

07/01/92 *Core Biochemistry Laboratory*, [**\$328,020**], In: Program Project: Calcium Regulation in Brain Aging and 06/30/97 Alzheimer's Disease; NIA; Project Director: P.W. Landfield; **\$4,093,027**

#### **Clinical Research**

03/01/91 *Depakote in the treatment of complex partial seizures, protocol # M88-194*; Abbott Laboratories; A.D. 02/28/93 Massey, P.I.; **\$34,070**

01/01/92 *The safety of intravenous valproate, protocol # M90-540*; Abbott Laboratories; A.B. Young, P.I.; **\$11,970**  
01/01/93

01/01/93 *Master agreement order for the clinical evaluation of antiepileptic drugs*; Epilepsy Branch, NINDS 92-01/31/97 17; A.B. Young, P.I.

02/01/98 *Losigamone as monotherapy in the treatment of complex partial seizures*; J.E. Cibula, P.I.; **\$876/**  
05/31/00 patient/week

09/01/05 *Neuroprotection exploratory trials in PD (NET-PD)*; NIH; F. Cambi, P.I. for this clinical site; 1<sup>st</sup> year 08/31/10 direct: **\$73,500**; Total period: **\$367,500**

07/01/06 *Neuroimaging studies of depression in Parkinson's disease*; NIH; L.X. Blonder, P.I.; 1<sup>st</sup> year direct: 06/30/10 **\$366,250**; Total period: **\$1,465,500**

05/17/06 *Neuroprotection exploratory trials in PD (NET-PD): Diversity recruitment study*; NIH; F. Cambi, P.I. for 11/30/10 this clinical site; 1<sup>st</sup> year direct: **\$21,465** (Budget period 12/1/06 – 11/30/07)

### ***Educational Research***

08/01/81 *Aging and the nervous system*; NIA #1 T32 AG 0084 (training grant); W.R. Markesbery, P.I.; **\$404,285**  
07/30/86

06/01/84 *Students in health professions*; NIH (training grant); J.S. Thompson, P.I.; **\$60,755**  
07/30/89

07/01/90 *Research training in environmental toxicology*; NIEH #1 T32 ES07266; T. Tobin, P.I.; **\$2,278,392**  
06/30/95

09/01/94 *Training program in the molecular and cellular basis of brain aging*; NIA; P. Wise, P.I.; **\$1,138,508**.  
06/30/99

07/01/95 *Research training in environmental toxicology*; NIEH #1 T32 ES07266; M. Vore, P.I.; **\$750,000**  
06/30/00

09/01/06 *Mechanisms of neurologic disease course*; NIMH #1 R25 MH079332-01; J Geddes, P.I.; 1<sup>st</sup> year  
08/31/08 direct: **\$39,070**; Total period: **\$79,703**

## XV Other

### *Invited Symposia*

- 1983 Co-director: 3rd Annual Neuroscience Symposium, University of Kentucky; Lexington, KY; 4/7-8
- 1984 Conference on Parkinson's disease and dementia; Scottsdale, AZ; 3/29-30
- 1985 Tegretol--where we are; St. Thomas, U.S. Virgin Islands; 1/5-9
- Excitatory amino acids and epilepsy; Fillerval, France; 9/2-5
- 1st National Clinical Symposium on Tourette Syndrome; New York, NY; 10/13-14
- 1991 Concepts in Molecular Medicine; Department of Veterans Affairs; Marconi Conference Center, San Francisco, CA; 3/13-16
- 1992 Neurobiological Basis of Epilepsy; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY; 4/29-5/3
- 2000 Co-Director: 2000 Annual Neurology Conference (Special Topics: Parkinson's disease, Dementia)
- 2004 6<sup>th</sup> International Conference on Kindling; Victoria, BC; 6/4-6.
- Update on Parkinsonism: Diagnosis and management; Louisville, KY; 10/1
- GDNF summit; Michael J. Fox Foundation; New York, NY; 10/14-15

### *Preparation of OSCE (Objective Structured Clinical Examination) Sites*

- 1996 Complex Partial Epilepsy
- 1997 Headache/Meningitis
- 1998 Senile Dementia of the Alzheimer's Type
- 1998 MRI/CT Images of the Head (6 images with case histories)
- 2000 TIA/Stroke

### *Workshops [Director]*

- 1981 Chairman, Animal Models Session; 1st International Giles de la Tourette Syndrome Symposium; New York, NY; 5/27-29
- 1985 Difficult seizure management; 16th Annual Family Medicine Review; Lexington, KY; 2/27, 5/22, 11/6
- 1986 Difficult seizure management; 17th Annual Family Medicine Review; Lexington, KY; 2/26, 5/21, 10/29

- 1989 Headaches: Malignant and benign; 20th Annual Family Medicine Review; Lexington, KY; 2/20, 5/22, 5/23, 11/13
- 1990 Headaches: Malignant and benign; 21st Annual Family Medicine Review; Lexington, KY; 2/26, 5/21, 5/23, 11/5, 11/7
- 1990 Discussion Leader; Comparative Aspects of Age-induced Plasticity in the Nervous System: Possible Consequences and Adaptive Value; University of Kentucky; 4/5-7
- 1991 Headaches: Malignant and benign; 22st Annual Family Medicine Review; Lexington, KY; 2/27, 5/20, 5/22, 10/28, 10/30
- 1992 Headaches: Malignant and benign; 23st Annual Family Medicine Review; Lexington, KY; 2/26, 5/18, 5/20
- 1993 Headaches: Malignant and benign; 24th Annual Family Medicine Review; Lexington, KY; 2/24, 5/24, 5/26, 11/1, 11/3.
- 1994 Headaches: Malignant and benign; 25th Annual Family Medicine Review; Lexington, KY; 2/21, 5/23, 5/25, 11/7, 11/9.
- 1995 Headaches: Malignant and benign; 26th Annual Family Medicine Review; Lexington, KY; 2/22, 5/22, 5/24, 11/6, 11/8.
- 1996 Headaches: Malignant and benign; 27th Annual Family Medicine Review; Lexington, KY; 2/28, 5/20, 5/22, 11/11, 11/13.
- 1997 Headaches: Malignant and benign; 28th Annual Family Medicine Review; Lexington, KY; 2/24, 5/19, 5/21, 11/10, 11/12.
- 1998 Headaches: Malignant and benign; 29th Annual Family Medicine Review; Lexington, KY; 2/25, 5/18, 5/20, 11/9, 11/11.
- 1999 Headaches: Malignant and benign; 30th Annual Family Medicine Review; Lexington, KY; 2/22, 5/23, 11/8
- 2000 Headaches: Malignant and benign; 31st Annual Family Medicine Review; Lexington, KY; 2/22, 5/22, 11/6
- 2001 Parkinson's Disease Update for 2001; 32nd Annual Family Medicine Review; Lexington, KY; 2/20, 5/22
- 2004 Parkinson's disease: A workshop for primary care providers; UK CME Office; Lexington, KY; 10/29